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Abstract
Rationale—People with CF treated with IV antibiotics for a pulmonary exacerbation (PEx) 
frequently fail to recover to baseline FEV1. The long-term impact of these events has not been 
studied.
Objectives—To determine if a patient’s spirometric recovery after a PEx is associated with time 
to next PEx within 1 year, the spirometric recovery after the next PEx, and/or the number of PEx 
episodes in the next 3 years.
Methods—We used data from the CF Foundation Patient Registry from 2004–2011. We 
randomly selected one PEx per patient that met inclusion/exclusion criteria. Patients were defined 
as Non-Responders if their best FEV1 (in liters) recorded in the 3 months after the PEx was <90% 
of the best FEV1 (in liters) in the 6 months before the PEx. We compared Responders and Non-
Responders using multivariable regression models.
Results—We randomly chose 13,954 PEx episodes that met inclusion/exclusion criteria. 2,762 
(19.8%) patients were classified as Non-Responders. Non-Responders had a shorter median time 
to the next PEx, 235 (95% CI 218, 252) days, versus >365 days for Responders. Thirty-four 
percent of Non-Responders at the initial PEx were also Non-Reponders at the next PEx, versus 
20% of Responders at the initial PEx. Non-Responders had more PEx episodes over the next 3 
years, 4.99 (95% CI 4.84, 5.13), than Responders, 3.46 (95% CI 3.41, 3.51).
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Conclusions—Poor recovery after a PEx is associated with a shorter time to the next PEx, 
increased risk of poor recovery at a second PEx, and more frequent subsequent PEx treatments.
Keywords
FEV1; risk factors; modeling
INTRODUCTION
People with cystic fibrosis (CF) experience periodic pulmonary exacerbations (PEx) that are 
characterized by worsening signs and symptoms of respiratory and overall health.1 PEx 
episodes treated with IV antibiotics are associated with worsening lung function, poorer 
quality of life, increased healthcare costs, and mortality.2–5 Several studies have 
demonstrated that recovery to spirometric baseline does not occur for a substantial 
proportion of patients following treatment with IV antibiotics for a PEx.6–10
This change in baseline lung function may be associated with further adverse outcomes, as 
patients with lower lung function have higher rates of PEx treatments, lower quality of life, 
and increased risk of death.2,11,12 A previous analysis found that 58% of patients who 
initially had poor spirometric recovery, defined as the best forced expiratory volume in 1 
second (FEV1) % predicted in the 3 months after a PEx that was less than 90% of the best 
FEV1 % predicted in the 6 months before the PEx, did not recover to the pre-exacerbation 
baseline in the 12 months after the PEx.7 In addition, patients treated with one or more 
courses of IV antibiotics for a PEx are at-risk for a shorter time to the next PEx,13 although 
it is unknown if the lack of spirometric recovery after a PEx is associated with further 
shortening of the time to the next PEx. Understanding this relationship is important in 
identifying patients most at-risk for future PEx treatments and their associated adverse 
outcomes.
We hypothesized that poor spirometric recovery after a PEx treated with IV antibiotics 
would be associated with a shorter time to the next PEx. We also tested whether patients 
with poor spirometric recovery at the initial PEx were at increased risk for poor recovery at 
the next recorded PEx and/or more treatments with IV antibiotics over the subsequent 3 
years. We evaluated our hypothesis using data from the national CF Foundation Patient 
Registry (CFFPR).14 Some of the results of these studies have been previously reported in 
the form of an abstract.15
MATERIALS AND METHODS
We included data from individuals enrolled in the CFFPR from January 1, 2004, through 
December 31, 2011. Data are entered into the CFFPR at each clinical encounter. Because 
PEx identification and treatment may have changed over this time period,16 and some 
patients would have had a PEx prior to 2004, we included one PEx randomly selected for 
each patient who did not have an organ transplantation during this time period. PEx episodes 
were chosen using the random function in Microsoft Excel among hospitalizations or home 
IV antibiotic courses recorded in the CFFPR that met inclusion and exclusion criteria. 
Hospitalizations or home IV antibiotic courses were excluded if they were for reasons other 
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than a PEx. PEx episodes were excluded if there was less than 12 months of data in the 
CFFPR before and after the PEx, or if there were no measurements of FEV1 recorded within 
the 6 months before and/or 3 months after the PEx. We excluded any PEx with a recorded 
treatment duration of <2 days, although our conclusions were not affected if we excluded 
PEx episodes of less than 3, 4, or 5 days. Patients were defined as Non-Responders if their 
best FEV1 measurement (in liters) in the 3 months after the PEx was <90% of the best FEV1 
measurement (in liters) in the 6 months before the PEx. FEV1 is reported as percent 
predicted values, calculated using Global Lung Initiative equations.17 We excluded any PEx 
from our analysis if another PEx occurred prior to the best FEV1 in the 3 months following 
the analyzed PEx.
Statistical Analyses
Descriptive statistics were used to summarize patient characteristics. We used multivariable 
Cox proportional hazards regression models to assess the difference between Responders vs 
Non-Responders for time to the next PEx within 365 days, calculated as the time from the 
start of the first course of IV antibiotics to the start of the second course. We determined the 
relative risk of being a Non-Responder at the next PEx, according to Responder/Non-
Responder status at the first PEx. We counted the number of IV antibiotic treatments for a 
PEx within the three years following the initial PEx and compared these using a negative 
binomial regression model.
We included the following variables in our regression models a priori based on a review of 
the literature for factors that may be associated with shorter time to the next PEx and/or poor 
spirometric recovery: undernourishment (defined as BMI <5th percentile according to CDC 
growth charts for children and <18.5 kg/m2 in adults), gender, age (categorized as 6–12, 13–
17, 18–25, and 25+ years old), persistent infection (defined as ≥2 positive cultures in the 
previous 12 months) with Pseudomonas aeruginosa, Burkholderia cepacia complex, or 
methicillin resistant Staphylococcus aureus (MRSA), on pancreatic enzyme replacement 
therapy, Medicaid or state insurance, allergic bronchopulmonary aspergillosis, 
nontuberculous Mycobacteria, 2 or more PEx episodes treated with IV antibiotics in the 
prior 12 months, baseline FEV1, CF-related diabetes, the time between the baseline FEV1 
measurement and the start of the PEx, and the duration of the IV antibiotics used to treat the 
PEx.6,7,9 We performed subset analyses by individually adding the decrease in FEV1 % 
predicted from baseline to the start of the PEx and the duration of IV antibiotics used to treat 
the initial PEx to the a priori models.8,18
A P value <0.05 was considered statistically significant for all analyses. All analyses are 
done in SAS version 9.4 (Cary, NC). The Institutional Review Board at the University of 
Wisconsin approved the study.
RESULTS
There were 35,516 patients with CF followed in the CFFPR during 2004–2011, 2,507 of 
whom had an organ transplantation during that time and were excluded from further 
analysis. During this time period, there were 197,085 hospitalizations or episodes with home 
IV antibiotics (Figure 1). From the 87,515 PEx episodes that met inclusion and exclusion 
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criteria, we randomly selected one PEx for the 15,134 patients who had at least one PEx. We 
excluded 1,180 (7.8%) of the initially selected PEx episodes where another PEx occurred 
prior to the best FEV1 recorded in the 3 months following the initial PEx. Of the remaining 
PEx episodes, 2,762 (19.8%) patients were classified as Non-Responders by comparing 
FEV1 in liters before and after the PEx. Non-Responders had lower mean (SD) FEV1 % 
predicted at baseline, 64.1 (26.3), and the start of the PEx, 51.8 (22.9), than Responders, 
71.8 (26.0) and 63.7 (24.0), respectively.
Non-Responders were more likely to be adult patients, undernourished, on Medicaid/state 
insurance, have persistent infections with P. aeruginosa and mucoid P. aeruginosa, have 
baseline FEV1 <80% predicted, and have CF-related diabetes (Table 1). Non-Responders 
also had more time between the baseline FEV1 assessment and the start of IV antibiotics, 
had a larger change in FEV1 % predicted from baseline, more PEx episodes treated with IV 
antibiotics in the previous 12 months, and were treated for a longer duration during the 
selected PEx. Adult patients were more likely to be Non-Responders (24.1%) than pediatric 
patients (14.8%), but Responder and Non-Responder differences were generally similar in 
separate pediatric and adult cohorts (online supplement Table E1). The proportion of female 
patients was higher among pediatric Non-Responders, but not adult Non-Responders.
In the 365 days after the initially selected PEx, 45% of Responders and 63% of Non-
Responders had another PEx. Kaplan-Meier analysis demonstrated that Non-Responders had 
a median (95% CI) time to the next PEx at least 4 months shorter than for Responders, 235 
(218, 252) days, as compared to >365 days for Responders (Figure 2). In a multivariable 
Cox proportional hazards model, being a Non-Responder was associated with a shorter time 
to the next PEx, HR 1.11 (95% CI 1.05, 1.18) (Table 2). Proportionality of the Non-
Responder covariate was confirmed by plotting Schoenfeld residuals. Each of the variables 
we selected a priori were significantly associated with a shorter time to the next PEx, except 
for nontuberculous Mycobacteria, ABPA, and the time between the baseline FEV1 
measurement and the initiation of IV antibiotics. Among the 7,678 patients with FEV1 
measured at the initiation of antibiotics, a decrease in FEV1 % predicted >15% predicted 
was not significantly associated with shorter time to the next PEx.
As reported previously,18 the number of exacerbations treated with IV antibiotics in the 
previous 12 months had the strongest association with a shorter time to the next PEx (Table 
2). Only 22% of patients with 0–1 PEx in the prior year had another PEx treated with IV 
antibiotics within 365 days of the initially selected PEx, compared to 85% of patients with 
≥2 PEx episodes in the prior year. Among patients with ≥2 PEx episodes in the prior year, 
the median (95% CI) time to the next PEx was 4 weeks shorter for Non-Responders [139 
(133, 143) days] than for Responders [168, (163, 172)].
In the 3 years after the PEx selected for this study, 10,998 (79%) patients had at least one 
more PEx recorded in the CFFPR, 8,682 of whom had sufficient measurements of FEV1 to 
classify Responder status. Among these patients, 1,797 (20.7%) were Non-Responders at the 
initial PEx and 2,015 (23.2%) were Non-Responders at the next recorded PEx. Only 1,392 
(20.2%) of patients who were Responders at the initial PEx were Non-Responders at the 
second. However, 623 (34.7%) of the Non-Responders at the initial PEx were also Non-
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Responders at the second. Compared with Responders at the initial PEx, the relative risk of 
being a Non-Responder at the next PEx was 1.7 (95% CI 1.6, 1.9) for Non-Responders at the 
initial PEx. Changes in FEV1 % predicted around these PEx episodes are shown in Figure 3. 
Patients who were Non-Responders at the first PEx episode had a mean (SD) baseline FEV1 
of 64.1 (26.3)% predicted at the start of the study, but the best recorded FEV1 in the 3 
months after the second PEx for patients who were Non-Responders at both PEx episodes 
decreased to a mean of 48.3 (20.8)% predicted. In contrast, patients who were Responders at 
the first PEx episode began the study with a baseline FEV1 of 71.8 (26.0)% predicted and 
patients who were Responders at both PEx episodes completed the study with FEV1 of 70.7 
(24.9)% predicted.
Given the differences in age and sex between Responders and Non-Responders at the initial 
PEx, we explored the relative risk of being a Non-Responder at the next PEx according to 
age and sex. The relative risk of being a Non-Responder at the next PEx was 0.63 (95% CI 
0.59, 0.69) for pediatric patients, compared with adult patients. The relative risk of being a 
Non-Responder at the next PEx was not statistically significantly different according to sex.
Patients who were Non-Responders at the randomly chosen PEx had a higher mean (95% 
CI) number of PEx treatments in the next 3 years, 4.99 (4.84, 5.13), as compared to 3.46 
(3.41, 3.51) for Responders at the initial PEx (Figure 4). The greatest difference in the 
number of PEx in the subsequent 3 years was between patients with 0–1 PEx in the prior 
year, 2.31 (2.27, 2.35), and patients with ≥2 PEx episodes in the prior year 5.75 (5.66, 5.85). 
The number of PEx treatments in the 3 years following the initial PEx remained significantly 
higher for Non-Responders compared to Responders in a multivariable negative binomial 
model (online supplement Table E2).
We then repeated our analyses, defining Non-Responders as patients whose best FEV1 
measurement in liters in the 3 months after the PEx was <100% of the best FEV1 
measurement in liters in the 6 months before the PEx. With this definition, 6,697 (48%) of 
patients met criteria for being a Non-Responder. Using this definition, 56% of Non-
Responders and 42% of Responders had another PEx within the next year, and Non-
Responders had a median (95% CI) time to the next PEx, 303 (289, 313) days, at least 2 
months shorter than Responders, >365 days. Being a Non-Responder at the initial PEx using 
the new definition was associated with one additional PEx treatment in the next 3 years, 4.29 
(4.21, 4.37), compared to 3.28 (3.21, 3.34) for Responders. Parameter estimates in the 
multivariable Cox and negative binomial regression models were generally unchanged.
DISCUSSION
Several recent observational reports have demonstrated that measurements of FEV1 
following a PEx treated with IV antibiotics often do not reach the levels recorded in the 
months preceding the PEx.6–10 None of these reports has explored the long-term outcomes 
that occur following poor recovery from a PEx. Herein, we have shown that poor spirometric 
recovery after a PEx is associated with a shorter time to the next PEx, increased risk of poor 
recovery at the next PEx, and more frequent PEx treatments over the following 3 years. Our 
results demonstrate that having poor spirometric recovery after a PEx may not be an isolated 
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event that patients can eventually recover from. Rather, these events have long-term 
implications for the health of people with CF and preventing or more adequately treating 
PEx episodes deserves significant attention.
Despite significant improvement in FEV1 in people with CF over the past decades, the rate 
of exacerbations treated with IV antibiotics has been stable for at least the past 20 years.14 
Waters et al. showed that a substantial proportion of overall FEV1 decline is attributable to 
exacerbations.19 Vandevanter et al. showed that having one course of IV antibiotics to treat a 
PEx is a very strong predictor of having another course of IV antibiotics,18 an effect also 
seen in our analysis. Although our analysis shows that poor PEx recovery is associated with 
a shorter time to the next PEx, it should be noted that the PEx history had a much stronger 
effect.
Each of these studies, including our report, is observational and cannot prove causality. 
Furthermore, there is limited data to support specific PEx treatments that can improve PEx 
recovery or longer-term poor outcomes. A recent study did demonstrate that adult patients 
treated with 7% hypertonic saline during a PEx were more likely to recover to baseline 
FEV1 than patients who received a saline placebo.20 An analysis of an observational study 
of adolescents and adults with CF treated with IV antibiotics for a PEx did not identify any 
best practices associated with improved outcomes.10 In the recently completed observational 
Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis 
(STOP) study, 35% of participants failed to reach 90% of previous baseline FEV1 % 
predicted.
Having poor recovery at the initial PEx was associated with a significantly increased risk of 
poor recovery after the second PEx. In our analysis, patients who were in the Non-
Responder group for both PEx episodes experienced a >15% decrease in mean FEV1 % 
predicted from before the initial PEx to after the second, over a time period that could be 
less than 2 years (Figure 3). Given the time between events, it is unlikely that the poor 
response at the initial PEx directly caused the poor recovery at the second PEx. It is possible 
that poor recovery may be a specific PEx phenotype that may be affected by characteristics 
of the patient, lung disease phenotype,21 PEx etiology (e.g., viral infections, medical 
nonadherence, microbiota), or PEx treatment decisions. Some patients are likely to return to 
clinic (and have FEV1 recorded) only when they are sick. This may place them at higher risk 
for repeated poor recovery if their “best follow up” FEV1 is recorded when they are sick. 
The CFFPR does not contain much of the above data, limiting our ability to further 
characterize this potential phenotype.
The large size of the CFFPR is a strength that allowed us to find associations between poor 
PEx recovery and long-term outcomes, but the observational nature of this study has 
limitations. First, it is possible that the association between poor PEx recovery and time to 
the next PEx is due to indication bias, i.e., clinicians recognize that patients did not respond 
as expected after the first treatment, so they choose to treat with IV antibiotics again. 
However, the median time between consecutive PEx treatments was over 7 months, so it is 
unlikely that clinicians treated these as linked events. Additionally, in surveys, the majority 
of treating physicians view PEx treatment as a success, even when FEV1 has not returned to 
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previous baseline values.22 Moreover, we excluded PEx episodes when a second PEx 
occurred prior to the best FEV1 in the 3 months after the chosen PEx to try and isolate the 
effects of a single PEx treatment. Risk factors for repeated PEx over very short periods have 
recently been reported.18 Second, shorter time to the next PEx may occur because of the 
new, lower baseline FEV1. More severe lung disease is a risk factor for more frequent PEx 
and poor recovery from PEx (Table 2). We adjusted for baseline FEV1 in our regression 
models, though it is possible that residual confounding is present. Third, our study, as with 
many epidemiologic studies, only addressed exacerbations treated with IV antibiotics. 
Exacerbations treated with IV antibiotics are important clinical end points associated with 
progression of lung disease, lower quality of life, and healthcare expenditures.2,3,5 However, 
our analysis does not address the many episodes treated with oral and/or inhaled 
antibiotics.23 These treatments may affect time to PEx and baseline FEV1,24,25 but the data 
is not well-tracked in the CFFPR. We chose Medicaid insurance as a marker of low 
socioeconomic status because it has been used previously in epidemiologic studies of 
CF.26,27 However, differences in healthcare utilization (e.g., number of well vs sick visits) 
and pulmonary function vary according to the specific marker of low socioeconomic 
status.28,29 For example, in the US, tobacco smoke exposure occurs most often in families 
with low socioeconomic status, and has independent effects on pulmonary outcomes. A 
recent report indicated that children exposed to tobacco smoke were more likely to have 
crackles and wheezes on exam.30 While disparities in CF lung disease related to 
socioeconomic status have not been explained by differential treatment of pulmonary 
exacerbations,27 the presence of these respiratory findings are associated with increased 
frequency of antibiotic courses.31 Tobacco smoke exposure is likely under-reported in the 
CFFPR, and so we did not evaluate it in our models. Finally, it should be acknowledged that 
recovering to within 90% of the previous baseline FEV1 is less than an ideal goal of therapy. 
This level of recovery was chosen to allow for the inherent variability in FEV1 
measurements,32,33 as well as the possibility that patients’ true best FEV1 may occur when 
they are not in clinic, and therefore not measured. The magnitude and statistical significance 
of our conclusions were not affected when we changed the definition of recovery to 
recovering to 100% of the previous baseline. It should be noted that 48.6% of patients failed 
to achieve this goal.
In conclusion, we have described an association between poor spirometric recovery from a 
PEx and a shorter time to the next PEx. As described previously, having recent 
exacerbation(s) treated with IV antibiotics is the strongest predictor of having a subsequent 
PEx treated with IV antibiotics. In this study, we have added to our understanding of this 
epidemiologic phenomenon, as poor recovery at the initial PEx is associated with an even 
shorter time to the next PEx in multivariable regression models that account for prior PEx 
history. Patients who have poor recovery at the initial PEx are at increased risk of poor 
recovery at a subsequent PEx. Further investigations are needed to understand the etiology 
and clinical impact of these epidemiologic associations. Most importantly, studies to 
optimize treatment and/or prevention of pulmonary exacerbations are urgently needed to 
minimize our patients’ risks of permanently losing lung function.
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Figure 1. 
Diagram of study cohort
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Figure 2. 
Kaplan–Meier time-to-PEx according to degree of spirometric recovery at a randomly 
selected PEx. According to our inclusion criteria, data was available for all patients for the 
first 12 months after the chosen PEx.
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Figure 3. 
Schema for changes in FEV1 % predicted between Responders (black lines) and Non-
Responders (grey lines) at the initially analyzed PEx and the next recorded PEx. Bracketed 
numbers indicate number of Responders and Non-Responders for each PEx. Grey boxes 
indicate PEx episodes. Dashed lines indicate patients may switch between groups between 
the two PEx episodes. The numbers next to the dashed lines represent the percent of patients 
from the initial PEx that become Responders and Non-Responders at the next PEx. Time 
between PEx episodes was at least 4 months longer than for Non-Responders (see text). 
Patients who remained Responders at both PEx episodes had preserved FEV1, while patients 
who were Non-Responders at both PEx episodes experienced a mean decline in FEV1 of 
nearly 16% predicted (see text).
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Figure 4. 
Number of PEx episodes over the next 3 years according to Responder status and prior-year 
PEx history at the analyzed PEx. The horizontal line represents the median number of PEx 
episodes, the box represent the interquartile range (IQR) between the 25th and 75th quartiles. 
The whiskers indicate the number of PEx episodes within 1.5 × IQR of the upper and lower 
quartiles. The ● represents the mean number of PEx episodes.
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Table 1
Cohort characteristics according to Responder status
Characteristic
Total (n=13,954)
N (%)
Responders (n=11,192)
N (%)
Non-Responders (n=2,762)
N(%)
Female gender 7,095 (50.9) 5,654 (50.5) 1,441 (52.2)
Adult patients (≥18 years old) 7,477 (53.6) 5,674 (50.7) 1,803 (65.3)
Undernourisheda 2,139 (15.3) 1,506 (13.5) 633 (22.9)
Pancreatic enzyme replacement therapy 13,079 (93.7) 10,471 (93.6) 2,608 (94.4)
Homozygous F508del 6,808 (48.8) 5,478 (48.9) 1,330 (48.1)
Heterozygous F508del 4,960 (35.6) 3,977 (35.5) 983 (35.6)
Other/Unknown mutations 2,186 (15.7) 1,737 (15.5) 449 (16.3)
Medicaid/state insurance 6,647 (47.6) 5,169 (46.2) 1,478 (53.5)
Persistent P. aeruginosa infectionb 7,182 (51.5) 5,540 (49.5) 1,642 (59.6)
Persistent B. cepacia complex infectionb 410 (2.9) 296 (2.6) 114 (4.1)
Persistent mucoid P. aerginosa infectionb 5,142 (36.9) 3,921 (35.0) 1,221 (44.2)
Persistent MRSA infectionb 2,934 (21.0) 2,275 (20.3) 659 (23.9)
Nontuberculous Mycobacteria 337 (2.4) 264 (2.4) 73 (2.6)
Allergic bronchopulmonary aspergillosis (ABPA) 1,053 (7.5) 815 (7.3) 238 (8.6)
Baseline FEV1
 <40% predicted 2,247 (16.1) 1,629 (14.6) 618 (22.4)
 40–59% predicted 2,805 (20.1) 2,092 (18.7) 713 (25.8)
 60–79% predicted 3,392 (24.3) 2,775 (24.8) 617 (22.3)
 ≥80% predicted 5,505 (39.5) 4,691 (41.9) 814 (29.5)
CF-related diabetes mellitus 3,117 (22.3) 2,314 (20.7) 803 (29.1)
Mean (SD) Mean (SD) Mean (SD)
Age (all patients) 21.2 (11.2) 20.8 (11.3) 23.1 (11.0)
Age (pediatric patients) 12.3 (3.5) 12.2 (3.5) 12.7 (3.6)
Age (adult patients) 29.0 (9.8) 29.1 (9.9) 28.7 (9.4)
BMI percentile (pediatric patients) 42.3 (26.9) 43.3 (26.7) 36.7 (27.6)
BMI (adult patients) 21.5 (4.0) 21.7 (3.6) 20.9 (5.0)
Time between baseline and start of IV antibiotics (weeks) 12.4 (8.2) 11.9 (8.3) 14.6 (7.7)
Change in FEV1 % predicted from baseline to start of IV 
antibioticsc
−15.1 (15.3) −13.1 (14.3) −23.9 (16.4)
PExs treated with IV antibiotics in the previous 12 months 1.8 (1.2) 1.6 (1.1) 2.3 (1.5)
Duration of PEx treatment (days) 16.0 (16.9) 15.5 (15.3) 18.2 (22.3)
a
Defined as BMI <5th percentile according to CDC growth charts for children and <18.5 kg/m2 in adults
b
Persistent infection defined as ≥2 positive culture in the 12 months before the PEx
c
Baseline defined as the best FEV1 % predicted in the 6 months before the PEx among 7,678 patients with FEV1 measured within 3 days of the 
start of IV antibiotics
Pediatr Pulmonol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sanders et al. Page 16
Table 2
Multivariable Cox proportional hazards model for time to next PEx. Hazard ratios (HR) >1 indicates increased 
risk of a PEx.
Parameter HR 95% CI
Non-Responder 1.11 1.05, 1.18
Female gender 1.16 1.10, 1.21
Age category (Reference: 6–12 years of age)
 13–17 years 1.24 1.15, 1.35
 18–25 1.15 1.06, 1.25
 25+ 1.02 0.93, 1.11
Undernourished 1.10 1.04, 1.18
Pancreatic insufficiency 1.16 1.04, 1.30
Medicaid/state insurance 1.22 1.16, 1.28
P. aeruginosa 1.13 1.07, 1.19
B. cepacia complex 1.20 1.06, 1.35
MRSA 1.09 1.03, 1.16
Nontuberculous Mycobacteria 1.13 0.97, 1.30
ABPA 1.02 0.94, 1.11
Baseline FEV1 % predicted (Reference: ≥80% predicted)
 <40% predicted 1.44 1.33, 1.57
 40–59% predicted 1.51 1.41, 1.63
 60–79% predicted 1.24 1.16, 1.33
CF-related diabetes mellitus 1.13 1.07, 1.20
Time between baseline and start of IV antibiotics (weeks) 1.00 0.99, 1.00
PExs treated with IV antibiotics in the previous 12 months (≥2) 7.28 6.88, 7.72
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